Categories: News

University Lab Partners Announces the Winners of Orange County’s 2024 Pitch. Launch. Grow. Competition

IRVINE, Calif., Aug. 19, 2024 /PRNewswire/ — University Lab Partners (ULP) is proud to announce the winners of the 4th annual Pitch. Launch. Grow. competition, a hallmark event that continues to spotlight innovation in life sciences, medical technology, and pediatrics. This year’s competition attracted over 40 applications, with startups competing for recognition across three specialized tracks.

ULP’s Pitch. Launch. Grow. competition spotlights innovation in life sciences, medical technology, and pediatrics.

The winners in the Life Science and Medical Technology tracks each receive a one-year sponsored lab bench at University Lab Partners, the premier wet lab incubator in Irvine, California. The Pediatric track winner will not only receive the lab bench sponsorship but also a $2,500 prize from the Consortium for Technology & Innovation in Pediatrics (CTIP)—an FDA-funded pediatric device accelerator—and a one-hour virtual mentorship session with Dr. Terence Sanger, MD, PhD, Chief Scientific Officer at CHOC Research. 

Dr. Sanger commended all participants, stating, “We extend our heartfelt gratitude to every founder in the Pediatric Device track. Your dedication and innovative spirit are exactly what the Pitch. Launch. Grow. competition aims to foster.”

Pitch. Launch. Grow. 2024 Winners:

Life Science – Hybrid Biotherapeutics Inc. & Cellecho Biotech
Medical Technology – Syntr Health Technologies, Inc. iPill Dispenser
Pediatric – Remmie Health

ULP’s life science startups are provided with unparalleled access to professional mentoring, consulting with Experts-in-Residence, networking events, and unique access to UCI’s technical core facilities. Since its inception in 2019, ULP has incubated 64 companies that have collectively raised over $535 million, successfully graduating eight startups into the broader market.

Konstantin Kazarian, CEO at Hybrid-Bio, shared, “As developers of a new solid tumor cell therapy, we’re thrilled by the interest the competition brought us. This recognition means a lot to Hybrid Biotherapeutics, and we look forward to collaborating with ULP and utilizing their state-of-the-art laboratory facilities.”

The 2024 Pitch. Launch. Grow. winners were selected by a distinguished panel of judges, representing leading organizations including Johnson & Johnson, Wilson Sonsini Goodrich & Rosati, CHOC, General Inception, Woodgreen Ventures, Xinetix, and D2M Venture Development.

Pitch. Launch. Grow. is made possible thanks to the generous sponsorship of Sunstone Management, Insperity, HATCHspaces, NexCore Group, and Wilson Sonsini Goodrich and Rosati. For more information, please visit https://www.universitylabpartners.org/our-events/pitch-launch-grow-demo-day

About University Lab Partners:

University Lab Partners (ULP) is a premier, nonprofit, wet lab incubator located in Orange County, CA. ULP operates 2 facilities in Irvine and Aliso Viejo, CA. ULP offers highly equipped wet lab facilities along with the benefits of accelerator services and peer-to-peer interactions among a life science-focused entrepreneurial community.

View original content to download multimedia:https://www.prnewswire.com/news-releases/university-lab-partners-announces-the-winners-of-orange-countys-2024-pitch-launch-grow-competition-302225667.html

SOURCE University Lab Partners

Staff

Recent Posts

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate…

12 hours ago

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for…

12 hours ago

KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research…

12 hours ago

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one…

12 hours ago

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed…

12 hours ago